Theravance Banks $100m As J&J Bets Big On IBD Drug

If the JAK inhibitor codenamed TD-1473 proves effective in Crohn’s disease and ulcerative colitis, the clinical, regulatory and commercial know-how in IBD from partner Janssen could help Theravance pocket $1bn.

Motorcycles
Future leader of the JAK in IBD? Theravance boosted by Janssen backing • Source: Shutterstock

Before even going into Phase II trials, Theravance Biopharma Inc. has bagged the biggest player in inflammatory bowel disease – Johnson & Johnson – as a partner for its pan-Janus kinase (JAK) inhibitor which the firm is already talking about as a transformational treatment for ulcerative colitis and Crohn's disease.

It is a big deal too, with Theravance getting an upfront payment of $100m from J&J's Janssen unit for TD-1473,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category